In this article, we will discuss the 5 Best Longevity and Anti-Aging Stocks to Buy. For deeper discussion and analysis, read 7 Best Longevity and Anti-Aging Stocks to Buy.
5. Intuitive Surgical, Inc. (NASDAQ:ISRG)
Short Percentage of Shares Outstanding: 2.05%
On June 2, Deutsche Bank reduced its price target on Intuitive Surgical, Inc. (NASDAQ:ISRG) to $366 from $440 while maintaining a Sell rating on the shares. The revised target reflects the firm’s updated valuation outlook for the company, although the adjustment did not alter its broader investment stance on the stock.
On May 28, Intuitive Surgical, Inc. (NASDAQ:ISRG) announced the promotion of Taylor Patton to the role of chief commercial and marketing officer, effective July 1. Patton, who most recently served as global senior vice president of the company’s endoluminal business, will become a member of the executive leadership team and succeed Henry Charlton, who is transitioning to the position of senior vice president of global business operations. Having spent nearly two decades with Intuitive Surgical, Patton has held a variety of leadership roles across commercial operations, marketing, and clinical application engineering, bringing extensive institutional knowledge and industry experience to his new position.
Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical, Inc. (NASDAQ:ISRG) produces robotic-assisted, minimally invasive surgery via its flagship da Vinci systems. Its primary involvement focuses on health span by providing less traumatic, more precise surgical options with quicker recovery times, enhancing how well people live as they age.
4. Stryker Corporation (NYSE:SYK)
Short Percentage of Shares Outstanding: 1.63%
On June 12, BofA lowered its price target on Stryker Corporation (NYSE:SYK) to $380 from $450 while maintaining a Buy rating on the shares. The firm cited a softer healthcare utilization environment highlighted by its services team and adopted a more conservative outlook for 2027 across the medical technology sector. The analyst also incorporated assumptions of increased inflationary pressures and reduced margin expansion potential for medtech companies, leading to lower earnings estimates for larger-cap names with exposure to procedure volumes and cost inflation.
On May 26, Stryker Corporation (NYSE:SYK) announced the European launch of its Pangea Plating System, a comprehensive plating platform designed to address a broad range of fracture patterns. The first clinical procedure using the system in Europe was successfully completed by Professor Alex Trompeter and his team at St. George’s University Hospital in London. The Pangea Plating System consists of non-active implant devices intended to provide temporary stabilization of bones and bone fragments, along with complementary instrumentation that supports implant fit and offers surgeons greater flexibility in fracture fixation procedures involving both upper and lower extremities.
Founded in 1941 and headquartered in Portage, Michigan, Stryker Corporation (NYSE:SYK) is a global medical technology company that designs and manufactures innovative orthopedic implants, surgical equipment, and neurotechnology. The company provides joint replacements, robotic surgical assistance, and spinal technologies that restore mobility and dramatically enhance the quality of life for aging individuals.
3. Eli Lilly and Company (NYSE:LLY)
Short Percentage of Shares Outstanding: 1.10%
On June 16, Austin-based neuroscience company 4E Therapeutics announced that it had been acquired by Eli Lilly and Company (NYSE:LLY). 4E Therapeutics is developing a pipeline of orally available MNK inhibitors designed to treat chronic pain by targeting the MNK-eIF4E signaling pathway in peripheral sensory neurons. Financial terms of the transaction were not disclosed.
On the same day, Eli Lilly and Company (NYSE:LLY) reported new Phase 1 data from the AJX-101 study showing that its investigational type II JAK2 inhibitor demonstrated a favorable safety profile and encouraging clinical activity in patients with myelofibrosis who had previously failed treatment with a type I JAK2 inhibitor. The therapy was specifically designed to selectively target the type II conformation of the JAK2 kinase, potentially offering a differentiated treatment option for patients who develop resistance to currently available therapies. Lilly recently added the program to its development pipeline through an acquisition, further expanding its oncology portfolio.
Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical leader focused on developing innovative medicines for diabetes, obesity, cancer, immunology, and neuroscience. The company has emerged as one of the key players in the longevity and healthy-aging space through its groundbreaking metabolic disease treatments, while continuing to invest heavily in next-generation therapies across multiple high-growth areas of healthcare.
2. Novo Nordisk A/S (NYSE:NVO)
Short Percentage of Shares Outstanding: 0.51%
On June 17, Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk A/S (NYSE:NVO) to DKK 325 from DKK 300 and maintained a Buy rating on the shares.
Earlier, on June 11, Novo Nordisk A/S (NYSE:NVO) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency approved the Wegovy pill as an adjunct to a reduced-calorie diet and increased physical activity. The approval makes the therapy the first oral GLP-1 receptor agonist authorized for weight management in adults living with obesity or overweight who also have at least one weight-related medical condition. The decision was supported by data from the Phase 3 OASIS 4 clinical trial and expands Novo Nordisk’s obesity treatment portfolio by offering patients a non-injectable alternative to existing therapies.
Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in chronic conditions like diabetes and obesity. It is primarily known for developing lifesaving GLP-1 therapies like Ozempic and Wegovy, but it also targets the underlying metabolic and cardiovascular diseases that reduce lifespan.
1. Novartis AG (NYSE:NVS)
Short Percentage of Shares Outstanding: 0.24%
On June 12, Novartis AG (NYSE:NVS) presented results from the RemIND trial at the European Academy of Allergy and Clinical Immunology Congress, demonstrating that Rhapsido achieved its primary endpoints across the three most common chronic inducible urticaria subtypes. The therapy became the first treatment to show efficacy in a global Phase III clinical trial for chronic inducible urticaria, with higher rates of complete responses observed by week 12 and clinical benefits emerging as early as week 2 in two of the subtypes. The findings suggest that Rhapsido may offer durable symptom relief for patients whose condition remains inadequately controlled despite treatment with second-generation H1-antihistamines.
On June 10, Novartis AG (NYSE:NVS) announced a multi-year collaboration with Orionis Biosciences to discover and develop molecular glue therapeutics targeting challenging disease pathways across multiple therapeutic areas. The agreement expands the companies’ existing relationship and will combine Orionis’ Allo-Glue platform and AI-driven discovery capabilities with Novartis’ drug development expertise to accelerate target identification, ligase profiling, and molecular glue optimization. Under the terms of the collaboration, Orionis will receive a $40 million upfront payment and may earn up to $1.4 billion in research, development, and commercial milestone payments, in addition to tiered royalties on future product sales.
Incorporated in March 1996 and headquartered in Basel, Switzerland, Novartis AG (NYSE:NVS) is a multinational pharmaceutical corporation that researches and develops innovative prescription medicines. The company explores the mTOR pathway via the rapamycin (sirolimus) class of compounds, aiming to delay age-related diseases and extend health span.
While we acknowledge the potential of NVS as a longevity and anti-aging stock, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NVS and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Under-the-Radar AI Stocks to Buy in 2026 and Top 10 Stocks That Members of Congress Own.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
